

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT

**CLINICAL TRIAL APPLICATION OF INNOVATIVE
MEDICINE “TQB2103 (Claudin18.2 ADC)” ACCEPTED BY CDE**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that clinical trial application of the Category 1 innovative medicine “TQB2103 (Claudin18.2 ADC)” for injection, self-developed by the Group, has been filed with and accepted by the Center for Drug Evaluation (“**CDE**”) of the National Medical Products Administration of the People’s Republic of China.

TQB2103 for injection is an antibody-drug conjugate (“**ADC**”) self-developed by the Group to target Claudin18.2 in advanced malignancies, the indication of the medicine. The antibody part of TQB2103 binds to the Claudin18.2 antigen on the surface of positive tumour cells and the ADC complex is transferred to lysosome via endocytosis, where the linker is enzymatically cleaved and a small-molecule toxin is released, causing DNA (deoxyribonucleic acid) damage and death of positive tumour cells, and even killing neighboring negative tumour cells by bystander effect.

The antibody end of TQB2103 is based on the Group’s proprietary Claudin18.2 monoclonal antibody, which has stronger target cell binding and endocytosis activity and better binding specificity, compared with the other most advanced Claudin18.2 monoclonal antibody under clinical trial. The design of the toxin molecule with high DAR (drug/antibody ratio) and low toxicity is expected to enhance the efficacy of TQB2103 while reducing toxicity and expanding the therapeutic window. The results of non-clinical studies showed that TQB2103 significantly inhibited the growth of Claudin18.2 positive human gastric and pancreatic cancer cells in nude mice; the toxicity of TQB2103 was under control in crab-eating

macaque toxicology experiments, with a large therapeutic safety window. The approval of TQB2103 for injection in clinical trials for advanced malignant tumours will further enrich the Group's product pipeline of innovative drugs in the field of oncology and may bring new treatment option to patients.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 10 February 2023

As at the date of this announcement, the Board of the Company comprises seven executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.